Avacta, Glythera link to develop drug conjugates

UK companies Avacta and Glythera have sealed a licensing deal to develop drug conjugates using their combined technologies. While specifics of the deal have not been disclosed, it was revealed that Avacta stands to receive development milestone payments and royalties on sales of any drug successfully developed by Glythera.The move follows completion of a proof-of-concept study by the firms which was geared towards showing that Avacta’s Affimer technology could be combined with Glythera’s Permalink conjugation chemistry “to provide a technically superior drug conjugate platform with shorter development times, simpler, more consistent production and greater chemical stability”.